Bladder Cancer, An Issue of Hematology/Oncology Clinics of North America, 1st Edition

Author :
By Joaquim Bellmunt, MD, PhD
This issue of Hematology/Oncology Clinics of North America, guest edited by Dr. Joaquin Bellmunt, is devoted to Bladder Cancer. Articles in this issue include: Diagnosis and Staging of Bladder Cancer; Epidemiology of Bladder Cancer; Molecular Biology ...view more
This issue of Hematology/Oncology Clinics of North America, guest edited by Dr. Joaquin Bellmunt, is devoted to Bladder Cancer. Articles in this issue include: Diagnosis and Staging of Bladder Cancer; Epidemiology of Bladder Cancer; Molecular Biology of Bladder Cancer; Pharmacogenomics in Bladder Cancer; Management of Non-muscle Invasive Bladder Cancer; Non-urothelial Bladder Cancer and Rare Variant Histologies; Management of UUT; New Trends in Surgical Management of Bladder Cancer; Bladder Preservation Strategies; Perioperative Therapy of Bladder Cancer (Neoadjuvant and Adjuvant); First Line Treatment and Prognostic Factors of Metastatic Disease: Platinum Eligible Patients; First Line Treatment of Metastatic Disease: Platinum Ineligible Patients; Salvage Therapy in Metastatic Disease; and Future Directions and Targeted Therapies in Bladder Cancer.
ISBN :
9780323359764
Publication Date :
13-04-2015
Stock Status :
Please allow 7-10 working days for delivery
Earn 13 Points
Add to Cart
This issue of Hematology/Oncology Clinics of North America, guest edited by Dr. Joaquin Bellmunt, is devoted to Bladder Cancer. Articles in this issue include: Diagnosis and Staging of Bladder Cancer; Epidemiology of Bladder Cancer; Molecular Biology of Bladder Cancer; Pharmacogenomics in Bladder Cancer; Management of Non-muscle Invasive Bladder Cancer; Non-urothelial Bladder Cancer and Rare Variant Histologies; Management of UUT; New Trends in Surgical Management of Bladder Cancer; Bladder Preservation Strategies; Perioperative Therapy of Bladder Cancer (Neoadjuvant and Adjuvant); First Line Treatment and Prognostic Factors of Metastatic Disease: Platinum Eligible Patients; First Line Treatment of Metastatic Disease: Platinum Ineligible Patients; Salvage Therapy in Metastatic Disease; and Future Directions and Targeted Therapies in Bladder Cancer.

Author Information
By Joaquim Bellmunt, MD, PhD, Director, Bladder Cancer Center Dana-Farber Cancer Institute Dana-Farber/Brigham and Women's Cancer Center Associate Professor, Harvard Medical School